The DOI matches its Crossref record.
Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 32
- Eisenhofer, 2004, Malignant pheochromocytoma: current status and initiatives for future progress, Endocr Relat Cancer, 11, 423, 10.1677/erc.1.00829 · DOI · Paper page
- Chrisoulidou, 2007, The diagnosis and management of malignant phaeochromocytoma and paraganglioma, Endocr Relat Cancer, 14, 569, 10.1677/ERC-07-0074 · DOI · Paper page
- Brouwers, 2005, Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma, Endocr Relat Cancer, 12, 263, 10.1677/erc.1.00913 · DOI
- Brouwers, 2006, Gene expression profiling of benign and malignant pheochromocytoma, Ann NY Acad Sci, 1073, 541, 10.1196/annals.1353.058 · DOI
- Strong, 2008, Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis, Surgery, 143, 759, 10.1016/j.surg.2008.02.007 · DOI · Paper page
- Suh, 2009, Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling, Ann Surg, 250, 983, 10.1097/SLA.0b013e3181b248bb · DOI
- Thouennon, 2010, Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival, Endocr Relat Cancer, 17, 637, 10.1677/ERC-10-0109 · DOI
- Waldmann, 2010, Microarray analysis reveals differential expression of benign and malignant pheochromocytoma, Endocr Relat Cancer, 17, 743, 10.1677/ERC-09-0118 · DOI
- Meyer-Rochow, 2010, MicroRNA profiling of benign and malignant pheochromocytoma identifies novel diagnostic and therapeutic targets, Endocr Relat Cancer, 17, 835, 10.1677/ERC-10-0142 · DOI
- John, 1999, Pheochromocytomas: can malignant potential be predicted?, Urology, 53, 679, 10.1016/S0090-4295(98)00612-8 · DOI · Paper page
- Amar, 2005, Genetic testing in pheochromocytoma or functional paraganglioma, J Clin Oncol, 23, 8812, 10.1200/JCO.2005.03.1484 · DOI · Paper page
- Brouwers, 2006, High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing, J Clin Endocrinol Metab, 91, 4505, 10.1210/jc.2006-0423 · DOI · Paper page
- Tippett, 1986, A re-evaluation of dopamine excretion in phaeochromocytoma, Clin Endocrinol (Oxf), 25, 401, 10.1111/j.1365-2265.1986.tb01706.x · doi:10.1111/j.1365-2265.1986.tb01706.x
- Proye, 1992, High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991, J Endocrinol Invest, 15, 651, 10.1007/BF03345810 · DOI
- Januszewicz, 2001, Dopamine and dopa urinary excretion in patients with pheochromocytoma – diagnostic implications, Blood Press, 10, 212, 10.1080/08037050152669729 · doi:10.1080/08037050152669729
- van der Harst, 2002, The value of plasma markers for the clinical behaviour of phaeochromocytomas, Eur J Endocrinol, 147, 85, 10.1530/eje.0.1470085 · DOI
- Eisenhofer, 2005, Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine, J Clin Endocrinol Metab, 90, 2068, 10.1210/jc.2004-2025 · DOI · Paper page
- Eisenhofer, 1986, Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase, Clin Chem, 32, 2030, 10.1093/clinchem/32.11.2030 · DOI · Paper page
- Lenders, 1993, Determination of metanephrines in plasma by liquid chromatography with electrochemical detection, Clin Chem, 39, 97, 10.1093/clinchem/39.1.97 · DOI · Paper page
- Rao, 2000, Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment, Hypertension, 36, 1045, 10.1161/01.HYP.36.6.1045 · DOI
- Amar, 2006, Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas, Ann NY Acad Sci, 1073, 383, 10.1196/annals.1353.042 · DOI
- Ayala-Ramirez, 2011, Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators, J Clin Endocrinol Metab, 96, 717, 10.1210/jc.2010-1946 · DOI · Paper page
- Remine, 1974, Current management of pheochromocytoma, Ann Surg, 179, 740, 10.1097/00000658-197405000-00029 · DOI · Paper page
- Proye, 1994, The pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?, World J Surg, 18, 467, 10.1007/BF00353738 · doi:10.1007/bf00353738
- Goldstein, 1999, Clinical experience over 48 years with pheochromocytoma, Ann Surg, 229, 755, 10.1097/00000658-199906000-00001 · DOI · Paper page
- Mannelli, 1999, Pheochromocytoma in Italy: a multicentric retrospective study, Eur J Endocrinol, 141, 619, 10.1530/eje.0.1410619 · DOI · Paper page
- Edstrom Elder, 2003, The management of benign and malignant pheochromocytoma and abdominal paraganglioma, Eur J Surg Oncol, 29, 278, 10.1053/ejso.2002.1413 · doi:10.1053/ejso.2002.1413
- Amar, 2005, Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma, J Clin Endocrinol Metab, 90, 2110, 10.1210/jc.2004-1398 · DOI · Paper page
- Feng, 2011, Predictive factors for malignant pheochromocytoma: analysis of 136 patients, J Urol, 185, 1583, 10.1016/j.juro.2010.12.050 · DOI
- Park, 2011, Predictive characteristics of malignant pheochromocytoma, Korean J Urol, 52, 241, 10.4111/kju.2011.52.4.241 · DOI
- Timmers, 2008, Biochemically silent abdominal paragangliomas in patients with mutations in the Sdhb gene, J Clin Endocrinol Metab, 93, 4826, 10.1210/jc.2008-1093 · DOI · Paper page
- Timmers, 2007, Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma, J Clin Oncol, 25, 2262, 10.1200/JCO.2006.09.6297 · DOI · Paper page
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationUpdate on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours
Lam, A. K.-Y. (2017) · Endocrine Pathology · doi:10.1007/s12022-017-9484-5 · Cited by 462
Personalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 417
Self-citationPathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
Kimura, N., Takayanagi, R., Takizawa, N., Itagaki, E., Katabami, T., Kakoi, N., Rakugi, H., Ikeda, Y., Tanabe, A., Nigawara, T., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0494 · Cited by 393
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
Metadata
- Authors
- Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., & Pacak, K.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 48
- Issue
- 11
- Pages
- 1739-1749
- ISSN
- 0959-8049
- Cited by
- 334
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- European Union 7th Framework Program (HEALTH-F2-2010-259735)
- Deutsche Forschungsgesellschaft
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. https://app.cochat.ai/papers/10.1016/j.ejca.2011.07.016
- The paper
- Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K., Timmers, H. J., & Pacak, K. (2012). Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2011.07.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.